J&J’s combination extends lives of cancer patients versus rival drug
Johnson & Johnson’s combination therapy for treating a certain form of cancer without chemotherapy, has been shown to extend patients' lives by more.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Johnson & Johnson’s combination therapy for treating a certain form of cancer without chemotherapy, has been shown to extend patients' lives by more.
The European Union regulators have greenlighted AstraZeneca’s drug to treat an advanced form of non-small cell lung cancer after it reduced the death.
Bharti Jayshankar December 13, 2024: AstraZeneca and Merck have announced long-term results from the OlympiA Phase 3 trial, showing that Lynparza (olaparib) significantly.
The US regulator has granted a breakthrough therapy designation to British-Swedish AstraZeneca and Japan’s Daiichi Sankyo experimental drug for treating a certain type.
Twenty-four European universities have formed a network to impart skills to 10,000 medical students across undergraduate degree programmes to address current and future.
British-Swedish AstraZeneca signed a $1.92 billion licensing agreement with CSPC Pharmaceutical Group to develop, manufacture and commercialize a compound to treat a metabolic.
British-Swedish AstraZeneca’s drug for treatment of a form of blood cancer has been granted a Priority Review in the US by the drug.
HQ Team September 22, 2024: AstraZeneca’s Flumist, the first at-home flu vaccine, got approved by the Food and Drug Administration, enabling consumers with.
Daiichi Sankyo and AstraZeneca’s breast cancer treatment ran into opposition from the UK’s healthcare spending watchdog, which wants Enhertu drug to be offered.
British-Swedish AstraZeneca has acquired Amolyt Pharma for $1.05 billion to gain access to Lyon, France-based company’s rare disease, late-stage pipeline.